4//SEC Filing
Bailey Jeffrey Allen 4
Accession 0001103021-22-000065
CIK 0001103021other
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 5:11 PM ET
Size
19.2 KB
Accession
0001103021-22-000065
Insider Transaction Report
Form 4
Bailey Jeffrey Allen
DirectorChief Executive Officer
Transactions
- Other
Common Stock
2022-03-22−105,133→ 0 total - Disposition to Issuer
Restricted Stock Units
2022-03-22−316,919→ 0 totalExercise: $0.00→ Common Stock (316,919 underlying) - Disposition to Issuer
Stock Options (right to buy)
2022-03-22−96,000→ 0 totalExercise: $5.18→ Common Stock (96,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2022-03-22−160,000→ 0 totalExercise: $4.23→ Common Stock (160,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2022-03-22−66,805→ 0 totalExercise: $4.36→ Common Stock (66,805 underlying) - Disposition to Issuer
Stock Options (right to buy)
2022-03-22−840,000→ 0 totalExercise: $3.60→ Common Stock (840,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2022-03-22−1,143,467→ 0 totalExercise: $3.66→ Common Stock (1,143,467 underlying)
Footnotes (4)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
- [F2]Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
- [F3]Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
- [F4]Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Documents
Issuer
BIODELIVERY SCIENCES INTERNATIONAL INC
CIK 0001103021
Entity typeother
Related Parties
1- filerCIK 0001500210
Filing Metadata
- Form type
- 4
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 5:11 PM ET
- Size
- 19.2 KB